Anti-cytokine treatment for Takayasu arteritis: State of the art

• DOI: 10.5582/irdr.3.29
• Publication Date: 2014-03-18T03:28:35Z
• Authors: Enrico Tombetti; Maria Chiara Di Chio; Silvia Sartorelli; Enrica Bozzolo; Maria Grazia Sabb...; Angelo A. Manfredi; Elena Baldissera
• Keywords: Takayasu's arteritis; Arteritis; Pathogenesis

Takayasu arteritis (TA) is a rare and idiopathic large-vessel typically affecting young women which has important morbidity mortality. There are no animal models of TA pathogenesis still mysterious. Clinical assessment lacks accurate activity indexes based on the integration clinical, laboratory radiological data. rarity hampered randomized clinical trials achievement high-quality evidence to guide activity. Prevention vascular progression, with progressive vessel wall remodelling hyperplasia, main therapeutic goal. Medical therapy remains mainstay management comprises traditional immunosuppressive agents anti-inflammatory drugs, such as steroids blockers pivotal cytokines, TNF-α IL-6. These strategies however only partially limit indicating that local molecular events involved. Here we discuss recent data suggesting selected cellular components lesions should be evaluated novel targets.